Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines:: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors

被引:90
|
作者
Boschelli, DH
Wu, ZP
Klutchko, SR
Showalter, HDH
Hamby, JM
Lu, GH
Major, TC
Dahring, TK
Batley, B
Panek, RL
Keiser, J
Hartl, BG
Kraker, AJ
Klohs, WD
Roberts, BJ
Patmore, S
Elliott, WL
Steinkampf, R
Bradford, LA
Hallak, H
Doherty, AM
机构
[1] Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA
[2] Parke Davis Pharmaceut Res, Dept Canc Res, Ann Arbor, MI 48105 USA
[3] Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[4] Parke Davis Pharmaceut Res, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA
关键词
D O I
10.1021/jm980398y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of 1 with a 4-(N,N-diethylaminoethoxy)phenylamino group yielded 2a, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogues that retained potency, including derivatives that were biased toward inhibition of the TK activity of PDGFr. Analogues of 2a with a 3-thiophene or an unsubstituted phenyl group at C-6 were the most potent inhibitors. Compound 54, which had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, respectively, was active in a variety of PDGF-dependent cellular assays and blocked the in vivo growth of three PDGF-dependent tumor lines.
引用
收藏
页码:4365 / 4377
页数:13
相关论文
共 50 条
  • [21] Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity
    Dietmar Gross
    Günther Bernhardt
    Armin Buschauer
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 589 - 599
  • [22] Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity
    Gross, Dietmar
    Bernhardt, Gunther
    Buschauer, Armin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (09) : 589 - 599
  • [23] Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors
    Hofer, MD
    Fecko, A
    Shen, RL
    Setlur, SR
    Pienta, KG
    Tomlins, SA
    Chinnaiyan, AM
    Rubin, MA
    NEOPLASIA, 2004, 6 (05): : 503 - 512
  • [24] Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase
    Mahboobi, Siavosh
    Uecker, Andrea
    Sellmer, Andreas
    Cenac, Christophe
    Hoecher, Heymo
    Pongratz, Herwig
    Eichhorn, Emerich
    Hufsky, Harald
    Truempler, Antje
    Sicker, Marit
    Heidel, Florian
    Fischer, Thomas
    Stocking, Carol
    Elz, Sigurd
    Boehmer, Frank-D.
    Dove, Stefan
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) : 3101 - 3115
  • [25] Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling
    Amanchy, Ramars
    Zhong, Jun
    Hong, Rosa
    Kim, James H.
    Gucek, Marjan
    Cole, Robert N.
    Molina, Henrik
    Pandey, Akhilesh
    MOLECULAR ONCOLOGY, 2009, 3 (5-6): : 439 - 450
  • [26] Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma
    Musumeci, Francesca
    Fallacara, Anna Lucia
    Brullo, Chiara
    Grossi, Giancarlo
    Botta, Lorenzo
    Calandro, Pierpaolo
    Chiariello, Mario
    Kissova, Miroslava
    Crespan, Emmanuele
    Maga, Giovanni
    Schenone, Silvia
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 127 : 369 - 378
  • [27] 7-Arylmethyl pyrrolo[2,3-d]pyrimidines as receptor tyrosine kinase inhibitors: Design, synthesis and biological evaluation.
    Zaware, Nilesh K.
    Gangjee, Aleem
    Yang, Jie
    Ihnat, Micheal
    CANCER RESEARCH, 2006, 66 (08)
  • [28] Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d] pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents
    Gangjee, Aleem
    Namjoshi, Ojas A.
    Yu, Jianming
    Ihnat, Michael A.
    Thorpe, Jessica E.
    Warnke, Linda A.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (10) : 5514 - 5528
  • [29] Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase
    Kubo, K
    Ohyama, S
    Shimizu, T
    Takami, A
    Murooka, H
    Nishitoba, T
    Kato, S
    Yagi, M
    Kobayashi, Y
    Iinuma, N
    Isoe, T
    Nakamura, K
    Iijima, H
    Osawa, T
    Izawa, T
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (23) : 5117 - 5133
  • [30] Discovery of new thieno[2,3-d]pyrimidines as EGFR tyrosine kinase inhibitors for cancer treatment
    Sobh, Eman A.
    Dahab, Mohammed A.
    Elkaeed, Eslam B.
    Alsfouk, Aisha A.
    Ibrahim, Ibrahim M.
    Metwaly, Ahmed M.
    Eissa, Ibrahim H.
    FUTURE MEDICINAL CHEMISTRY, 2023, 15 (13) : 1167 - 1184